Nebulized Heparin Composition for Cancer Therapy Lung Damage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chemoradiation therapies for cancer treatment cause significant pulmonary damage, including inflammation, fibrosis, and coagulation, with limited effective treatments available.
Innovation Solution
Administering a nebulized composition of low molecular weight heparin, optionally with N-acetylcysteine, directly to the lungs via inhalation to target and reduce radiation- or chemotherapy-induced lung damage by inhibiting inflammatory cytokines and promoting anti-inflammatory effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If systemic heparin or other anti-coagulant therapies are used to treat pulmonary damage, then coagulation is inhibited, but bleeding risks and other systemic side effects increase
Solution Approach 1:
The patent applies local quality by delivering heparin specifically to the lungs through nebulized inhalation rather than systemic administration. This localized delivery inhibits coagulation in the pulmonary tissue where it is needed while avoiding systemic circulation, thereby preventing bleeding risks and other systemic side effects associated with conventional systemic heparin therapy.
Solution Approach 2:
The patent uses an intermediary delivery system (nebulizer) to transfer heparin from a usable form to a deliverable form. The nebulized composition serves as an intermediary that carries heparin directly to the lung tissue, enabling localized action without requiring systemic circulation, thus resolving the contradiction between effective coagulation inhibition and bleeding risk.
2Object-affected harmful factors
If conventional treatments for radiation-induced lung damage are used, then some symptom relief is achieved, but the treatments do not effectively address the underlying pathology and may have significant side effects
Solution Approach 1:
The patent applies parameter changes by modifying the molecular weight of heparin to create low molecular weight heparin (LMWH) with specific molecular weight ranges (3-8 kDa). This parameter change optimizes the drug's properties for pulmonary delivery and local action, improving treatment efficacy for radiation-induced lung damage while reducing systemic side effects compared to conventional heparin formulations.
Solution Approach 2:
The patent replaces conventional systemic administration mechanisms with a nebulized inhalation system. This substitution allows direct delivery of therapeutic agents to the lung tissue, improving treatment reliability and efficacy while avoiding the non-specific effects of systemic circulation-based treatments.
3Object-affected harmful factors
If multiple systemic medications are administered to treat lung damage, then comprehensive coverage is achieved, but the complexity of treatment and risk of drug interactions increase
Solution Approach 1:
The patent applies universality by using low molecular weight heparin as a multi-functional agent that simultaneously addresses multiple aspects of lung damage including inflammation, fibrosis, and coagulation. This single agent with multiple mechanisms of action simplifies the treatment regimen compared to requiring multiple separate medications, while maintaining comprehensive coverage of the pathological processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method effectively reduces lung inflammation and fibrosis, slows cancer progression, and prevents coagulation without systemic side effects, maintaining the efficacy of concurrent cancer therapies.
Implementation Method 1
administering to the subject via inhalation a nebulized composition comprising a heparin
Data Source
AI summary
Described herein are compositions and methods for treating lung damage associated with cancer therapy, for example radiation-induced lung damage or chemotherapy-induced lung damage. Lung damage may be treated by administering heparin, optionally formulated with or administered concurrently with N-acetylcysteine. The compositions may be nebulized and administered via inhalation to treat lung damage.